{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '1.2.3 Schedule of events Part 3 (Safety monitoring phase Year 3 - Year 5)', 'Table 3 - Safety monitoring phase Year 3-5', 'Safety monitoring phase', 'Visit Daya', 'M25', 'M26', 'M27', 'M28', 'M29', 'M30', 'M31', 'M32', 'M33', 'M34', 'M35', 'M36b', 'Relapse Visit', 'M37', 'M38', 'M39', 'M40', 'M41', 'M42', 'M43', 'M44', 'M45', 'M46', 'M47', 'M48b', 'M49', 'M50', 'M51', 'M52', 'M53', 'M54', 'M55', 'M56', 'M57', 'M58', 'M59', 'M606', 'Visit number', 'V29', 'V30', 'V31', 'V32', 'V33', 'V34', 'V35', 'V36', 'V37', 'V38', 'V39', 'V40', 'V41', 'V42', 'V43', 'V44', 'V45', 'V46', 'V47', 'V48', 'V49', 'V50', 'V51', 'V52', 'V53', 'V54', 'V55', 'V56', 'V57', 'V58', 'V59', 'V60', 'V61', 'V62', 'V63', 'V64', 'Efficacy:', 'EDSS', 'X', 'X', 'Brain MRI', 'SDMT', 'BVMT-R Test', 'PedsQL (QoL Questionnaire)/', 'Ped. NeuroQol (sub-comp.)', 'Safety:', 'Physical examination', 'X', \"Clinical chemistry laboratories' d,e\", 'X', 'X', 'Hematology (Differential CBC)d,f', 'X', 'X', 'Thyroid Function Testsd', 'X', 'Urinalysisg', 'X', 'Serum Creatinineh and alanine', 'X', 'aminotransferased', 'Lymphocyte phenotyping', 'Samples for antibodies to Study Drug', 'Tanner Staging', 'AE/SAE recording (if any)', 'Concommitant medications', 'Vital Signs', 'X', 'X', 'HPV (yearly)', 'Abbreviations: AE: adverse event; BVMT-R: brief visuospatial memory test-revised, CBC: complete blood count; EDSS: Expanded Disability Status Scale; M: month(s);', 'MRI: magnetic resonance imaging; Neuro-QoL: quality of life in neurological disorders; Ped: paediatric; QoL: quality of life; SAE: serious adverse event; SDMT: symbol digit modality test.', 'a All study visits during safety monitoring phase except the M36,M48 and M60 visits can be performed within +7 days.', 'b M36, M48 and M60 Study visits can be performed within +4 weeks for these visits, to allow for scheduling of assessments.', 'Property of the Sanofi Group - strictly confidential', 'Page 19', 'VV-CLIN-0254406 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'C The MRI assessments will be available to investigators to assess safety.', \"d At these visits, in some countries, there is an option for the nurse to obtain samples for clinical chemistry laboratories, hematology, thyroid function tests, urinalysis and serum creatinine at the patient's home. This\", 'will therefore be considered a home visit. In this case, a phone call from the Investigator to review AE and concomitant medication is allowed. If home nursing cannot be implemented, local laboratories may be', 'used for sample collection and shipment to the central laboratory, as per local regulations. These visits are to be followed by telephone calls from the study site to assess AEs and concomitant medications.', 'e', 'Complete chemistry panel (glucose, creatinine, blood urea nitrogen (BUN), sodium, potassium, chloride, bicarbonate, magnesium, calcium uric acid, aspartate aminotransferase (AST), alanine aminotransferase', '(ALT), gamma-glutamyl transpeptidase (GGT), lactate dehydrogenase (LDH), total bilirubin, direct/indirect bilirubin, alkaline phosphatase, inorganic phosphorus, total protein, albumin, globulin, albumin/globulin', 'ratio, triglycerides, cholesterol and creatine phosphokinase (CPK). It is preferred that CBCs with platelet count, and monitoring for any cytopenia as well as serum creatinine, and urinalysis with microscopy be', 'analyzed at the central laboratory, but under special circumstances (eg, if patient is unable to visit the study center weekly or monthly, or results are needed urgently), the assay may be performed at a local', 'laboratory provided that test results are entered into the e-CRF in a timely manner.', 'f', 'Hematology and differential panel (hemoglobin, hematocrit, red blood cell count, mean corpuscular hemoglobin, white blood cell count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets). It is', 'preferred that CBCs with platelet count, and monitoring for any cytopenia as well as serum creatinine, and urinalysis with microscopy be analyzed at the central laboratory, but under special circumstances (eg, if', 'patient is unable to visit the study center weekly or monthly, or results are needed urgently), the assay may be performed at a local laboratory provided that test results are entered into the e-CRF in a timely', 'manner.', 'g Urinalysis (pH, ketones, protein, glucose, blood, urobilinogen, bilirubin, microscopic sediment, specific gravity). However for study visits that only require laboratory sampling, home nursing or local laboratories may', 'be used for sample collection and shipment to the central laboratory, as per local regulations. These visits are to be followed by telephone calls from the study site to assess AEs and concomitant medications.', 'h For alemtuzumab-treated patients, abnormal serum creatinine and/or urinalysis findings should be followed according to the guidelines provided in the protocol (guidelines will be based on current adult program', 'guidelines)', 'i', 'Testing will be conducted for human papillomavirus (HPV) infection as and when recommended by local public health authorities. If the testing is positive, the patient may be eligible after the condition has resolved', 'as per the Investigator opinion (eg, follow-up HPV test is negative or cervical abnormality has been effectively treated). An annual follow-up is recommended.', 'Property of the Sanofi Group - strictly confidential', 'Page 20', 'VV-CLIN-0254406 5.0']\n\n###\n\n", "completion": "END"}